Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual cl...
Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021
About this item
Full title
Author / Creator
Publisher
England: Cambridge University Press
Journal title
Language
English
Formats
Publication information
Publisher
England: Cambridge University Press
Subjects
More information
Scope and Contents
Contents
We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating...
Alternative Titles
Full title
Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7fd4453495214ef5aa455c88beb396c0
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7fd4453495214ef5aa455c88beb396c0
Other Identifiers
ISSN
2732-494X
E-ISSN
2732-494X
DOI
10.1017/ash.2022.298
